China clinical trials delayed as outbreak persists
China’s drawn-out fight against the coronavirus outbreak is disrupting hundreds of clinical trials being run by both global and domestic drug makers in the city of Wuhan, Reuters reports.
Heavy travel bans are making it difficult for the studies to stay on schedule, though a number of drug developers said it is too soon to speculate on long-term impacts. Some hospitals have suspended their drug trials, while some contract research organizations report patients having difficulty getting to the trial sites.
So far, the outbreak’s impact on drug R&D has been limited, though. As STAT’s Kate Sheridan reports, for biotech startups that primarily operate in regions other than Hubei province, or CROs operating multiple sites across China such as Wuxi AppTec, the initial disruption has been relatively mild.
Heavy travel bans are making it difficult for the studies to stay on schedule, though a number of drug developers said it is too soon to speculate on long-term impacts. Some hospitals have suspended their drug trials, while some contract research organizations report patients having difficulty getting to the trial sites.
So far, the outbreak’s impact on drug R&D has been limited, though. As STAT’s Kate Sheridan reports, for biotech startups that primarily operate in regions other than Hubei province, or CROs operating multiple sites across China such as Wuxi AppTec, the initial disruption has been relatively mild.
.png)
No hay comentarios:
Publicar un comentario